On 10 June 2010 GlaxoSmithKline (GSK) acquired Laboratorios Phoenix, a leading Argentine pharmaceutical business, for approximately US$253 million. GSK will gain full ownership of Phoenix in a move to accelerate sales growth and further extend its pharmaceutical portfolio in Argentina and the Latin America region.
GSK acquires Argentine generics’ maker Laboratorios Phoenix
Home/Pharma News
|
Posted 25/06/2010
0
Post your comment

Phoenix is a leading Argentine pharmaceutical company focused on the development, manufacturing, marketing and sale of branded generic products. Phoenix has been established for more than 70 years in the Argentine market and has a broad portfolio covering the cardiology, gastroenterology, neuroscience, metabolic, urology and analgesic therapy areas.
GSK expects this move to rapidly expand their presence in the fast growing Argentine market. In addition, President for Emerging Markets GSK, Mr Abbas Hussain, said “Phoenix’s broad portfolio and rich pipeline of branded generics will enable us to bring more medicines of value to patients in Argentina”.
With this agreement, GSK gains access to a broad portfolio of branded generic pharmaceutical products, as well as a manufacturing facility near Buenos Aires and Phoenix’s established primary care sales force. In addition, GSK will acquire an extensive local pipeline of branded generics and product development capability in Argentina.
Argentina has recently been identified by IMS as being one of the most important emerging markets, with a total market value of US$3 billion and the third highest growth rate at 22%.
Combined, GSK Argentina and Phoenix would currently rank third in the Argentine pharmaceutical market.
Reference:
GSK Press Release, GSK drives Latin America growth strategy with acquisition of Laboratorios Phoenix, June 10, 2010
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment